Clinical Trial Update: Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases [Phase 2, Phase 3]

View source ↗

Summary

A study evaluating anti-CEA CAR-T plus chemotherapy versus chemotherapy alone in pancreatic cancer with liver metastases has been withdrawn (Phase 2/3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Cancer
• Pancreatic Cancer

Drugs mentioned

• Anti-CEA CAR-T (CEA-targeted CAR-T cells)
• Chemotherapy (chemotherapy)

Snippet

Sponsor: Sorrento Therapeutics, Inc. | Conditions: Malignant Tumor of Pancreas Metastatic to Liver | Phase 2, Phase 3 | Status: WITHDRAWN